256 related articles for article (PubMed ID: 20406834)
1. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.
Chen LF; Cohen EE; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2489-95. PubMed ID: 20406834
[TBL] [Abstract][Full Text] [Related]
2. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
[TBL] [Abstract][Full Text] [Related]
3. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
[TBL] [Abstract][Full Text] [Related]
4. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
[No Abstract] [Full Text] [Related]
5. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.
Boeckx C; Baay M; Wouters A; Specenier P; Vermorken JB; Peeters M; Lardon F
Oncologist; 2013; 18(7):850-64. PubMed ID: 23821327
[TBL] [Abstract][Full Text] [Related]
6. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
7. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
10. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.
Kao J; Sikora AT; Fu S
Curr Cancer Drug Targets; 2009 Dec; 9(8):931-7. PubMed ID: 20025602
[TBL] [Abstract][Full Text] [Related]
11. A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Box C; Mendiola M; Gowan S; Box GM; Valenti M; Brandon Ade H; Al-Lazikani B; Rogers SJ; Wilkins A; Harrington KJ; Eccles SA
Eur J Cancer; 2013 Jul; 49(11):2512-21. PubMed ID: 23582742
[TBL] [Abstract][Full Text] [Related]
12. [Research progress of squamous cell carcinoma of head and neck EGFR targeted therapy resistance mechanisms].
Song Q; Li X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):184-90. PubMed ID: 25989677
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
14. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
15. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
[TBL] [Abstract][Full Text] [Related]
16. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
18. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
19. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Zaryouh H; De Pauw I; Baysal H; Peeters M; Vermorken JB; Lardon F; Wouters A
Med Res Rev; 2022 Jan; 42(1):112-155. PubMed ID: 33928670
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
Psyrri A; Seiwert TY; Jimeno A
Am Soc Clin Oncol Educ Book; 2013; ():246-55. PubMed ID: 23714515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
